License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug ...

As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts Dr. Bordey to direct the ...

Explore Cassava Sciences stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SAVA. Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After ...

Cassava Sciences said its chief medical officer, Dr. James Kupiec, is retiring, effective May 9. Under Kupiec, the clinical-stage biotechnology company completed a clinical trial program in ...

AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel ...

Cassava Sciences Shares Lower Premarket on $40 Million Penalty to Settle Doctored Data Claims ...

Dr. Bordey will lead Cassava’s ongoing research and development efforts Cassava Sciences, Inc. (NASDAQ: SAVA), is a clinical-stage biotechnology company focused on developing novel ...

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pivotal... ByInvesting.com • Oct 02, 2023 Cassava Sciences Reports ...

Cassava Sciences Inc. advanced stock charts by Barron's. View SAVA historical stock data and compare to other stocks, and exchanges.

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer's Who Received Drug Candidate Simufilam Continuously, ...